Apple juice greatly reduces systemic exposure to atenolol

Hyewon Jeon, In Jin Jang, Seunghwan Lee, Kyoichi Ohashi, Tsutomu Kotegawa, Ichiro Ieiri, Joo Youn Cho, Seo Hyun Yoon, Sang Goo Shin, Kyung Sang Yu, Kyoung Soo Lim

研究成果: ジャーナルへの寄稿記事

31 引用 (Scopus)

抄録

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT •Atenolol is an antihypertensive drug, of which negligible amounts are metabolized. •Fruit juices may decrease the oral absorption of drugs by inhibiting intestinal drug transporters, as demonstrated in vitro and in vivo. WHAT THIS STUDY ADDS •The pharmacokinetic characteristics of atenolol were determined according to the SLCO2B1 genotype after apple juice administration in healthy Korean volunteers. •Apple juice ingestion markedly reduced the systemic exposure to atenolol, but genetic variations in SLCO2B1 were unlikely to contribute substantial variability to the pharmacokinetics of atenolol. AIM Fruit juice reduces the plasma concentrations of several β-adrenoceptor blockers, likely by inhibiting OATP2B1-mediated intestinal absorption. The aim of this study was to investigate the effects of apple juice on the pharmacokinetics of atenolol. METHODS Twelve healthy Korean volunteers with genotypes of SLCO2B1 c.1457C> T (*1/*1 (n= 6) and *3/*3 (n= 6)) were enrolled in this study. In a three-phase, one-sequence crossover study, the pharmacokinetics (PK) of atenolol was evaluated after administration of 50mg atenolol. Subjects received atenolol with either 300ml water, 1200ml apple juice or 600ml apple juice. RESULTS Apple juice markedly reduced the systemic exposure to atenolol. The geometric mean ratios (95% confidence intervals) of apple juice:water were 0.18 (0.13, 0.25, 1200ml) and 0.42 (0.30, 0.59, 600ml) for the AUC(0,tlast). In this study, the PK parameters of atenolol responded in a dose-dependent manner to apple juice. CONCLUSIONS Apple juice markedly reduced systemic exposure to atenolol. The genetic variation of SLCO2B1 c.1457C>T had a minimal effect on the pharmacokinetics of atenolol when the drug was administered with water or apple juice.

元の言語英語
ページ(範囲)172-179
ページ数8
ジャーナルBritish Journal of Clinical Pharmacology
75
発行部数1
DOI
出版物ステータス出版済み - 1 2013

Fingerprint

Atenolol
Malus
Pharmacokinetics
Water
Healthy Volunteers
Genotype
Pharmaceutical Preparations
Intestinal Absorption
Cross-Over Studies
Adrenergic Receptors
Antihypertensive Agents
Area Under Curve
Eating

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology

これを引用

Apple juice greatly reduces systemic exposure to atenolol. / Jeon, Hyewon; Jang, In Jin; Lee, Seunghwan; Ohashi, Kyoichi; Kotegawa, Tsutomu; Ieiri, Ichiro; Cho, Joo Youn; Yoon, Seo Hyun; Shin, Sang Goo; Yu, Kyung Sang; Lim, Kyoung Soo.

:: British Journal of Clinical Pharmacology, 巻 75, 番号 1, 01.2013, p. 172-179.

研究成果: ジャーナルへの寄稿記事

Jeon, H, Jang, IJ, Lee, S, Ohashi, K, Kotegawa, T, Ieiri, I, Cho, JY, Yoon, SH, Shin, SG, Yu, KS & Lim, KS 2013, 'Apple juice greatly reduces systemic exposure to atenolol', British Journal of Clinical Pharmacology, 巻. 75, 番号 1, pp. 172-179. https://doi.org/10.1111/j.1365-2125.2012.04324.x
Jeon, Hyewon ; Jang, In Jin ; Lee, Seunghwan ; Ohashi, Kyoichi ; Kotegawa, Tsutomu ; Ieiri, Ichiro ; Cho, Joo Youn ; Yoon, Seo Hyun ; Shin, Sang Goo ; Yu, Kyung Sang ; Lim, Kyoung Soo. / Apple juice greatly reduces systemic exposure to atenolol. :: British Journal of Clinical Pharmacology. 2013 ; 巻 75, 番号 1. pp. 172-179.
@article{f0542f7118994e46886579ec76dde7b2,
title = "Apple juice greatly reduces systemic exposure to atenolol",
abstract = "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT •Atenolol is an antihypertensive drug, of which negligible amounts are metabolized. •Fruit juices may decrease the oral absorption of drugs by inhibiting intestinal drug transporters, as demonstrated in vitro and in vivo. WHAT THIS STUDY ADDS •The pharmacokinetic characteristics of atenolol were determined according to the SLCO2B1 genotype after apple juice administration in healthy Korean volunteers. •Apple juice ingestion markedly reduced the systemic exposure to atenolol, but genetic variations in SLCO2B1 were unlikely to contribute substantial variability to the pharmacokinetics of atenolol. AIM Fruit juice reduces the plasma concentrations of several β-adrenoceptor blockers, likely by inhibiting OATP2B1-mediated intestinal absorption. The aim of this study was to investigate the effects of apple juice on the pharmacokinetics of atenolol. METHODS Twelve healthy Korean volunteers with genotypes of SLCO2B1 c.1457C> T (*1/*1 (n= 6) and *3/*3 (n= 6)) were enrolled in this study. In a three-phase, one-sequence crossover study, the pharmacokinetics (PK) of atenolol was evaluated after administration of 50mg atenolol. Subjects received atenolol with either 300ml water, 1200ml apple juice or 600ml apple juice. RESULTS Apple juice markedly reduced the systemic exposure to atenolol. The geometric mean ratios (95{\%} confidence intervals) of apple juice:water were 0.18 (0.13, 0.25, 1200ml) and 0.42 (0.30, 0.59, 600ml) for the AUC(0,tlast). In this study, the PK parameters of atenolol responded in a dose-dependent manner to apple juice. CONCLUSIONS Apple juice markedly reduced systemic exposure to atenolol. The genetic variation of SLCO2B1 c.1457C>T had a minimal effect on the pharmacokinetics of atenolol when the drug was administered with water or apple juice.",
author = "Hyewon Jeon and Jang, {In Jin} and Seunghwan Lee and Kyoichi Ohashi and Tsutomu Kotegawa and Ichiro Ieiri and Cho, {Joo Youn} and Yoon, {Seo Hyun} and Shin, {Sang Goo} and Yu, {Kyung Sang} and Lim, {Kyoung Soo}",
year = "2013",
month = "1",
doi = "10.1111/j.1365-2125.2012.04324.x",
language = "English",
volume = "75",
pages = "172--179",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Apple juice greatly reduces systemic exposure to atenolol

AU - Jeon, Hyewon

AU - Jang, In Jin

AU - Lee, Seunghwan

AU - Ohashi, Kyoichi

AU - Kotegawa, Tsutomu

AU - Ieiri, Ichiro

AU - Cho, Joo Youn

AU - Yoon, Seo Hyun

AU - Shin, Sang Goo

AU - Yu, Kyung Sang

AU - Lim, Kyoung Soo

PY - 2013/1

Y1 - 2013/1

N2 - WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT •Atenolol is an antihypertensive drug, of which negligible amounts are metabolized. •Fruit juices may decrease the oral absorption of drugs by inhibiting intestinal drug transporters, as demonstrated in vitro and in vivo. WHAT THIS STUDY ADDS •The pharmacokinetic characteristics of atenolol were determined according to the SLCO2B1 genotype after apple juice administration in healthy Korean volunteers. •Apple juice ingestion markedly reduced the systemic exposure to atenolol, but genetic variations in SLCO2B1 were unlikely to contribute substantial variability to the pharmacokinetics of atenolol. AIM Fruit juice reduces the plasma concentrations of several β-adrenoceptor blockers, likely by inhibiting OATP2B1-mediated intestinal absorption. The aim of this study was to investigate the effects of apple juice on the pharmacokinetics of atenolol. METHODS Twelve healthy Korean volunteers with genotypes of SLCO2B1 c.1457C> T (*1/*1 (n= 6) and *3/*3 (n= 6)) were enrolled in this study. In a three-phase, one-sequence crossover study, the pharmacokinetics (PK) of atenolol was evaluated after administration of 50mg atenolol. Subjects received atenolol with either 300ml water, 1200ml apple juice or 600ml apple juice. RESULTS Apple juice markedly reduced the systemic exposure to atenolol. The geometric mean ratios (95% confidence intervals) of apple juice:water were 0.18 (0.13, 0.25, 1200ml) and 0.42 (0.30, 0.59, 600ml) for the AUC(0,tlast). In this study, the PK parameters of atenolol responded in a dose-dependent manner to apple juice. CONCLUSIONS Apple juice markedly reduced systemic exposure to atenolol. The genetic variation of SLCO2B1 c.1457C>T had a minimal effect on the pharmacokinetics of atenolol when the drug was administered with water or apple juice.

AB - WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT •Atenolol is an antihypertensive drug, of which negligible amounts are metabolized. •Fruit juices may decrease the oral absorption of drugs by inhibiting intestinal drug transporters, as demonstrated in vitro and in vivo. WHAT THIS STUDY ADDS •The pharmacokinetic characteristics of atenolol were determined according to the SLCO2B1 genotype after apple juice administration in healthy Korean volunteers. •Apple juice ingestion markedly reduced the systemic exposure to atenolol, but genetic variations in SLCO2B1 were unlikely to contribute substantial variability to the pharmacokinetics of atenolol. AIM Fruit juice reduces the plasma concentrations of several β-adrenoceptor blockers, likely by inhibiting OATP2B1-mediated intestinal absorption. The aim of this study was to investigate the effects of apple juice on the pharmacokinetics of atenolol. METHODS Twelve healthy Korean volunteers with genotypes of SLCO2B1 c.1457C> T (*1/*1 (n= 6) and *3/*3 (n= 6)) were enrolled in this study. In a three-phase, one-sequence crossover study, the pharmacokinetics (PK) of atenolol was evaluated after administration of 50mg atenolol. Subjects received atenolol with either 300ml water, 1200ml apple juice or 600ml apple juice. RESULTS Apple juice markedly reduced the systemic exposure to atenolol. The geometric mean ratios (95% confidence intervals) of apple juice:water were 0.18 (0.13, 0.25, 1200ml) and 0.42 (0.30, 0.59, 600ml) for the AUC(0,tlast). In this study, the PK parameters of atenolol responded in a dose-dependent manner to apple juice. CONCLUSIONS Apple juice markedly reduced systemic exposure to atenolol. The genetic variation of SLCO2B1 c.1457C>T had a minimal effect on the pharmacokinetics of atenolol when the drug was administered with water or apple juice.

UR - http://www.scopus.com/inward/record.url?scp=84871124271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871124271&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2012.04324.x

DO - 10.1111/j.1365-2125.2012.04324.x

M3 - Article

VL - 75

SP - 172

EP - 179

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 1

ER -